{
  "docId": "019de072-c9ff-713b-84f0-a86291a57ca3",
  "docSlug": "36aaeca628c43c1081cab946857c1896",
  "documentTitle": "Navidea Biopharmaceuticals | Investor Presentation Deck | 18 slides",
  "authorId": "navidea-biopharmaceuticals",
  "authorName": "Navidea Biopharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 18,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "The slide uses a chemical structure diagram to illustrate the platform's modularity (dextran spine, mannose targeting, and replaceable payload).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-c9ff-713b-84f0-a86291a57ca3/6",
  "deckHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3",
  "deckJsonHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3.json",
  "deckAnchorHref": "/decks/019de072-c9ff-713b-84f0-a86291a57ca3#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.265
      },
      "kind": "image",
      "text": "Chemical structure diagram of the Manocept platform",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f8e506b-83d3-42c1-8be7-ea0f4de8e972",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Target CD206 receptor on macrophages- best-in-class affinity; Flexible Manocept platform allows switching of payloads for diagnostics or therapeutics indications; Macrophages are involved in a very large number of diseases; FDA/EMA approved (favorable regulatory pathway); Over 600,000 injections with no drug-related serious adverse events (safe core molecule)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb52193e-5ee4-4741-b2ef-603d57ffc21b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Our Core Technology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57489a9b-3c04-4d2a-bb6c-d9662756d24e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Targeted Binding to Activated Macrophages",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7438dc76-08d7-4e1e-8ab5-fab10f4c8ced",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 7,
      "from": 6,
      "beatId": "d2dd142b-15d3-48ed-824d-1609c86d15f8",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The sections on targeted binding to activated macrophages and key features of the Manocept platform present the solution approach.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}